Evidence map›Paper›PMID 32913966›Full record

ArticleJCO precision oncology2017

Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine.

Derrick S Haslem, Hanlee P Ji, James M Ford, Lincoln D Nadauld

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Derrick S Haslemand , Dixie Regional Medical Center, Saint George, UT; , , and , Stanford University School of Medicine, Stanford, CA.
Hanlee P Jiand , Dixie Regional Medical Center, Saint George, UT; , , and , Stanford University School of Medicine, Stanford, CA.
James M Fordand , Dixie Regional Medical Center, Saint George, UT; , , and , Stanford University School of Medicine, Stanford, CA.
Lincoln D Nadauldand , Dixie Regional Medical Center, Saint George, UT; , , and , Stanford University School of Medicine, Stanford, CA.
Stanford University · US

Funding

WHOLE YEAST GENOME TRANSCRIPTIONAL AND FUNCTIONAL GENE MAPS--A FEASIBILITY STUDYP01HG000205 · NHGRI · STANFORD UNIVERSITY · PI HOWE, ROGER THOMAS, JI, HANLEE P · 1990 to 2016
$120.9M
An Integrated Approach to the Validation of Novel Gastric Cancer OncogenesK08CA166512 · NCI · STANFORD UNIVERSITY · PI NADAULD, LINCOLN D. · 2012 to 2016
$689k
NCI NIH HHS K08 CA166512NHGRI NIH HHS P01 HG000205
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID32913966
PMCPMC7446358
OpenAlexW2730775742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.